Debate: Optimal Treatment for HER2-Positive Colorectal Cancer After First-Line Treatment: Chemotherapy

Debate Speaker(s)

• 

  Jeffrey A. Meyerhardt, MD, MPH

  Dana-Farber Cancer Institute, Harvard Medical School